2023 Form 5500 filing — Leidos Biomedical Research, Inc. Capital Accumulation Plan
Plain-English filing summary
According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20240730133427NAL0020083633001) for Leidos Biomedical Research, Inc. Capital Accumulation Plan, reported by Leidos Biomedical Research, Inc. under EIN 33-0653185 and plan number 003. It reports 2,942 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).
- EFAST2 acknowledgement
- 20240730133427NAL0020083633001
- Filing year
- 2023
- Form type
- 2
- Plan sponsor
- Leidos Biomedical Research, Inc.
- EIN
- 33-0653185
- Plan number
- 003
- Location
- Frederick, MD
- Participants
- 2,942
- Schedules available
- Schedule H, Schedule C
- Received date
- not reported in the loaded dataset
Reported financial snapshot (2023)
- Total assets (EOY)
- $305,047,981
- Total liabilities (EOY)
- $0
- Net assets (EOY)
- $305,047,981
- Employer contributions
- $8,849,582
- Participant contributions
- $24,315,100
- Total income / additions
- $80,331,778
- Benefits paid
- $13,742,252
- Administrative expenses
- $69,103
- Total expenses
- $13,810,724
- Net increase / (decrease)
- $66,521,054
- Schedule source
- Schedule H
Reported service provider compensation (Schedule C)
| Provider | Service | Direct comp. | Indirect comp. |
|---|---|---|---|
| The Vanguard Group, Inc. | NONE | $69,661 | $0 |